{
  "source": "PA-Notification-Zoryve.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1395-5\nProgram Prior Authorization/Notification\nMedication Zoryve® (roflumilast)\nP&T Approval Date 9/2022, 9/2023, 11/2023, 2/2024, 12/2024\nEffective Date 3/1/2025\n1. Background:\nZoryve (roflumilast) 0.3% cream is a phosphodiesterase 4 inhibitor indicated for topical treatment\nof plaque psoriasis, including intertriginous areas, in patients 6 years of age and older. Zoryve\n(roflumilast) foam is indicated for the treatment of seborrheic dermatitis in adult and pediatric\npatients 9 years of age and older. Zoryve (roflumilast) 0.15% cream is indicated for the topical\ntreatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of\nage and older.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Zoryve 0.3% cream will be approved based upon the following criterion:\n(1) Diagnosis of plaque psoriasis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zoryve 0.3% cream will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\nB. Seborrheic Dermatitis\n1. Initial Authorization\na. Zoryve foam will be approved based upon the following criterion:\n(1) Diagnosis of seborrheic dermatitis\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2024 UnitedHealthcare Services, Inc.\n1\na. Zoryve foam will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\nC. Atopic Dermatitis\n1. Initial Authorization\na. Zoryve 0.15% cream will be approved based upon the following criterion:\n(1) Diagnosis of mild to moderate atopic dermatitis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Zoryve 0.15% cream will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\nAuthorization will be issued f",
    "d for 12 months.\n2. Reauthorization\na. Zoryve 0.15% cream will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Zoryve cream [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; July\n2024.\n2. Zoryve foam [package insert]. Westlake Village, CA: Arcutis Biotherapeutics, Inc.; December\n2023.\nProgram Prior Authorization/Notification – Zoryve (tapinarof)\nChange Control\n9/2022 New program.\n9/2023 Annual review with no change to clinical criteria.\n© 2024 UnitedHealthcare Services, Inc.\n2\n11/2023 Updated background to include patients 6 years of age and older.\nUpdated reference.\n2/2024 Added criteria for Zoryve foam for seborrheic dermatitis. Updated\nbackground and reference.\n12/2024 Added criteria for Zoryve 0.15% cream for atopic dermatitis. Updated\nplaque psoriasis criteria to specify 0.3% cream. Updated all\nauthorizations to 12 months. Updated background and reference.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}